Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014

By Gilberto de Lima Lopes Junior. Indian Journal of Medical and Paediatric Oncology, 2014

677 citations recorded by the source corpus.

The treatment of metastatic colorectal cancer is one of clinical and multidisciplinary oncology’s biggest successes in recent decades. Today, not only does the median overall survival in recent clinical trials consistently exceed 24 months (and 30 months in patients with wild RAS), compared to 6 months or less with supportive treatment alone before the 1990s, but we can also treat patients with metastatic disease confined to the liver with a curative intent.[1,2] Well trained teams of professionals, including medical, and surgical oncologists, and the use of new drugs are two of the main factors leading to this improvement. Classical chemotherapeutic agents such as fluoropyrimidines, oxaliplatin, and irinotecan, and targeted treatments such as bevacizumab, cetuximab, panitumumab, aflibercept, and regorafenib are part of our current armamentarium.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/812f49f58988d8fb328e57236cadd1d1b44dbf93